Gerresheimer has announced plans to separate its moulded glass business following a comprehensive strategic review aimed at assessing growth opportunities and competitive positioning.
The company, which serves the pharmaceutical, biotech, and cosmetic sectors, plans to initiate a sales process for this business unit.
Go deeper with GlobalData
The moulded glass division, strengthened by the acquisition of Bormioli Pharma, operates eight production facilities across the Americas, Europe, and Asia.
In 2024, this unit generated approximately €735m ($850.4m) in revenues, with an adjusted earnings before interest, taxes, depreciation, and amortisation margin of around 20%.
As part of the integration of Bormioli Pharma, Gerresheimer is establishing the moulded glass business as a standalone entity.
Further updates on this transition will be shared during the upcoming capital markets day scheduled for 15 October 2025.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe combined operations provide a diverse range of glass packaging solutions, including bottles, jars, and containers, for the pharmaceutical, cosmetic, and food and beverage sectors.
In addition, the acquisition has allowed Gerresheimer to expand its offerings, including primary packaging and dosing systems for pharmaceuticals while enhancing opportunities for integrating high-value plastic solutions within the industry.
Gerresheimer CEO Dietmar Siemssen said: “We see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group.
“As part of our strategic transformation, Gerresheimer will focus even stronger on the portfolio of systems and solutions for the pharma and biotech industry.”
The company has invested around €100m in upgrading its facility in Lohr am Main, Germany, by installing an energy-efficient oxy-hybrid furnace over the past two years.
In December 2024, Gerresheimer announced the addition of a new syringe production hall at its site in Skopje, North Macedonia, with an investment of more than €100m.
